Oncology

Latest News

The report suggests a TBS cutoff value of 3 will serve as a meaningful prognostic tool in HCC, but differences in patient populations and imaging techniques may affect the value of that cutoff, the authors noted. | Image credit: Jo Panuwat D - stock.adobe.com
HCC Tumor Burden Score Predicts Long-Term Outcomes Following MWA

May 7th 2025

Patients with a high tumor burden score had poorer outcomes following microwave ablation, the investigators found.

Doctor showing lung x ray | Image credit: didesign – stock.adobe.com
Tarlatamab Safety Varies Between Clinical and Real-World SCLC Trials

May 6th 2025

CureCancer | Image Credit: © MMPhoto21-sotck.adobe.com
COA 2025: Insight, Innovation, and Independent Strength

May 5th 2025

COA logo | Image Credit: © Amy Kinnamon
Community Oncology Reacts to Trump's Drug Pricing Executive Order

May 2nd 2025

Melanoma & Skin Cancer Awareness Month | Image credit: Waseem Ali Khan - stock.adobe.com
5 Things You Should Know About Skin Cancer

May 2nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

BMS, Celgene Discuss $74 Billion Acquisition During JP Morgan Healthcare Conference
January 8th 2019

BMS, Celgene Discuss $74 Billion Acquisition During JP Morgan Healthcare Conference

Jaime Rosenberg
Bristol-Meyers Squibb (BMS) and Celgene kicked off the 37th Annual JP Morgan Healthcare Conference by discussing their leading drugs, near-term launches, and early pipeline assets.
Dr Brian Koffman: It Is Critical That Patients Educate Themselves and Leverage Their Advantages
January 5th 2019

Dr Brian Koffman: It Is Critical That Patients Educate Themselves and Leverage Their Advantages

As a physician, Brian Koffman, MDCM, DCFP, DABFM, MS Ed, medical director, CLL Society, was able to leverage his medical and scientific knowledge during treatment for his chronic lymphocytic leukemia (CLL), and he encourages other patients to educate themselves on their illnesses in order to receive the best care.
Dr Sibel Blau Explains What the Results of OCM Have Shown
December 31st 2018

Dr Sibel Blau Explains What the Results of OCM Have Shown

Results from the first 2 performance periods of the Oncology Care Model (OCM) highlighted areas where Northwest Medical Specialties was doing well and areas it could improve, said Sibel Blau, MD, medical oncologist at Northwest Medical Specialties, PLLC.
Future of Therapy and Final Thoughts on Myelofibrosis
December 28th 2018

Future of Therapy and Final Thoughts on Myelofibrosis

Symptoms and Patient Progression
December 28th 2018

Symptoms and Patient Progression

Evolution of Myelofibrosis and Efficacy & Toxicity of Therapy
December 28th 2018

Evolution of Myelofibrosis and Efficacy & Toxicity of Therapy

Pacritinib and the Practical Implications
December 28th 2018

Pacritinib and the Practical Implications

Comparison of Ruxolitinib vs Fedratinib and Practical Implications
December 28th 2018

Comparison of Ruxolitinib vs Fedratinib and Practical Implications

Emerging Agents and Review of Fedratinib
December 28th 2018

Emerging Agents and Review of Fedratinib

Long-Term Survival and Adverse Effects With Ruxolitinib
December 28th 2018

Long-Term Survival and Adverse Effects With Ruxolitinib

Mechanism of JAK Inhibitors and a Review of Ruxolitinib
December 28th 2018

Mechanism of JAK Inhibitors and a Review of Ruxolitinib

NCCN Guidelines and Anemia Treatment
December 28th 2018

NCCN Guidelines and Anemia Treatment

Goals of Therapy and Starting Therapy for Myelofibrosis
December 28th 2018

Goals of Therapy and Starting Therapy for Myelofibrosis

Prognosis and Risk Stratification of Myelofibrosis
December 28th 2018

Prognosis and Risk Stratification of Myelofibrosis

Diagnosis of Myelofibrosis
December 28th 2018

Diagnosis of Myelofibrosis

Overview of Myelofibrosis
December 28th 2018

Overview of Myelofibrosis

Chemotherapy for Solid Tumors Associated With Increased Risk of AML, MDS
December 28th 2018

Chemotherapy for Solid Tumors Associated With Increased Risk of AML, MDS

Laura Joszt, MA
Patients who are treated with chemotherapy for their solid tumors have an increased risk of therapy-related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML) despite advances in chemotherapy regimens, according to a new study in JAMA Oncology.
This Year in Managed Care: 2018 Recap
December 28th 2018

This Year in Managed Care: 2018 Recap

This week, we recapped the top news from 2018 with a look at policy changes, new research, decisions at the polls, and more.
Males With MPN Have More Aggressive Disease Biology, Independent of Other Factors
December 28th 2018

Males With MPN Have More Aggressive Disease Biology, Independent of Other Factors

Jackie Syrop
Males with myeloproliferative neoplasms have worse survival compared with females with MPN, even when adjusted for age at presentation, presenting phenotype, and molecular characteristics.
The Most-Read Articles From Evidence-Based OncologyTM for 2018
December 27th 2018

The Most-Read Articles From Evidence-Based OncologyTM for 2018

Mary Caffrey
From chimeric antigen receptor T-cell therapy to value-based contracting, reimbursement issues dominated reader interest.
Reimbursement With Treatment for Multiple Myeloma
December 27th 2018

Reimbursement With Treatment for Multiple Myeloma

Studies Presented at ASH 2018 and the Outlook for Myeloma
December 27th 2018

Studies Presented at ASH 2018 and the Outlook for Myeloma

MRD Testing and Relapsed/Refractory Multiple Myeloma Treatment Options
December 27th 2018

MRD Testing and Relapsed/Refractory Multiple Myeloma Treatment Options

Transplant Patients' Options, CoMMpass Study, and Doublet Versus Triplet Therapy
December 27th 2018

Transplant Patients' Options, CoMMpass Study, and Doublet Versus Triplet Therapy

Dr Robert Daly Discusses How Clinical Pathways Can Reduce Disparities in Breast Cancer
December 25th 2018

Dr Robert Daly Discusses How Clinical Pathways Can Reduce Disparities in Breast Cancer

There can be great disparities across the country and across races when it comes to cancer care, but clinical pathways can help standardize care so everyone gets the most efficacious treatments, said Robert Daly, MD, MBA, medical oncologist, Memorial Sloan Kettering Cancer Center.
Challenges and Opportunities in the Oncology Care Model
December 23rd 2018

Challenges and Opportunities in the Oncology Care Model

Laura Joszt, MA
The practices that have been participating in CMS’ Oncology Care Model have undergone significant practice transformation in order to be successful in the program. However, even after being in the model for 2 years, there are still remaining opportunities for investment.
Diabetes, Cancer Interviews Among Most-Watched Videos of 2018
December 20th 2018

Diabetes, Cancer Interviews Among Most-Watched Videos of 2018

Laura Joszt, MA
Throughout the year, The American Journal of Managed Care® (AJMC®) offered a number of video programs, including Peer Exchange discussions and interviews, on a range of topics. Here are the most-watched videos published by AJMC® in 2018.
Dr Barbara McAneny Explains the Current Focus of Care Management in Oncology
December 20th 2018

Dr Barbara McAneny Explains the Current Focus of Care Management in Oncology

Keeping people with cancer out of the hospital is a low-hanging fruit that is of huge benefit to patients, explained Barbara L. McAneny, MD, president of the American Medical Association.
Dr Michael Kolodziej Reflects on OCM and What Might Come After
December 19th 2018

Dr Michael Kolodziej Reflects on OCM and What Might Come After

The Oncology Care Model (OCM) is not a sustainable model, but while it finishes out the 5-year pilot, CMS will likely be fine-tuning bundled payments in medical oncology, said Michael Kolodziej, MD, vice president and chief innovation officer at ADVI Health, Inc.
Report Assesses Degree of Alignment Between ASCO, ESMO Oncology Frameworks
December 18th 2018

Report Assesses Degree of Alignment Between ASCO, ESMO Oncology Frameworks

Allison Inserro
A joint assessment comparing the results of value frameworks created by the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) found that the frameworks produce comparable measures of the clinical benefits of new cancer therapies in roughly two-thirds of more than 100 drug comparisons examined.
<1
...
313233343536373839
...
184>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo